title: Efficacy of influenza vaccination and tamiflu® treatment--comparative studies with Eurasian Swine influenza viruses in pigs.
abstract: Recent epidemiological developments demonstrated that gene segments of swine influenza A viruses can account for antigenic changes as well as reduced drug susceptibility of pandemic influenza A viruses. This raises questions about the efficacy of preventive measures against swine influenza A viruses. Here, the protective effect of vaccination was compared with that of prophylactic Tamiflu® treatment against two Eurasian swine influenza A viruses. 11-week-old pigs were infected by aerosol nebulisation with high doses of influenza virus A/swine/Potsdam/15/1981 (H1N1/1981, heterologous challenge to H1N1 vaccine strain) and A/swine/Bakum/1832/2000 (H1N2/2000, homologous challenge to H1N2 vaccine strain) in two independent trials. In each trial (i) 10 pigs were vaccinated twice with a trivalent vaccine (RESPIPORC® FLU3; 28 and 7 days before infection), (ii) another 10 pigs received 150 mg/day of Tamiflu® for 5 days starting 12 h before infection, and (iii) 12 virus-infected pigs were left unvaccinated and untreated and served as controls. Both viruses replicated efficiently in porcine respiratory organs causing influenza with fever, dyspnoea, and pneumonia. Tamiflu® treatment as well as vaccination prevented clinical signs and significantly reduced virus shedding. Whereas after homologous challenge with H1N2/2000 no infectious virus in lung and hardly any lung inflammation were detected, the virus titre was not and the lung pathology was only partially reduced in H1N1/1981, heterologous challenged pigs. Tamiflu® application did not affect these study parameters. In conclusion, all tested preventive measures provided protection against disease. Vaccination additionally prevented virus replication and histopathological changes in the lung of homologous challenged pigs.
authors: IDT Biologika GmbH, Dessau-Rosslau, Germany.
authors: Ralf
authors: R
authors: Duerrwald
authors: Michael
authors: M
authors: Schlegel
authors: Katja
authors: K
authors: Bauer
authors: Théophile
authors: T
authors: Vissiennon
authors: Peter
authors: P
authors: Wutzler
authors: Michaela
authors: M
authors: Schmidtke
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D057221:Influenza A Virus, H1N2 Subtype / Q000276:immunology; D007252:Influenza Vaccines; D008297:Male; D009439:Neuraminidase / Q000037:antagonists & inhibitors / Q000737:chemistry; D009976:Orthomyxoviridae Infections / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D053139:Oseltamivir / Q000494:pharmacology / Q000627:therapeutic use*; D034421:Sus scrofa; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry; D014779:Virus Replication
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D007252:Influenza Vaccines; D014764:Viral Proteins; D053139:Oseltamivir; D009439:Neuraminidase
references: Emerg Infect Dis. 2010 Jan;16(1):96-9
references: 20031049
references: Viral Immunol. 2006 Summer;19(3):373-82
references: 16987057
references: Vaccine. 2011 Mar 24;29(15):2712-9
references: 21310191
references: J Gen Virol. 2009 Sep;90(Pt 9):2119-23
references: 19592456
references: Intervirology. 2006;49(5):286-93
references: 16809934
references: J Virol. 2005 Oct;79(19):12416-24
references: 16160169
references: Vaccine. 2001 Aug 14;19(31):4479-86
references: 11483274
references: Virology. 1983 Sep;129(2):521-3
references: 6623931
references: Euro Surveill. 2009 Feb 19;14(7):
references: 19232229
references: Nat Med. 2004 Dec;10(12 Suppl):S82-7
references: 15577936
references: Bull World Health Organ. 1981;59(1):75-8
references: 6973418
references: Nature. 2009 Jun 25;459(7250):1122-5
references: 19516283
references: Antiviral Res. 2007 Sep;75(3):219-26
references: 17445913
references: J Infect Dis. 1994 May;169(5):1125-9
references: 8169406
references: Med Microbiol Immunol. 2012 Feb;201(1):61-72
references: 21688167
references: Intervirology. 2003;46(1):66-70
references: 12566701
references: Nature. 2009 Aug 20;460(7258):1021-5
references: 19672242
references: J Virol. 2009 May;83(9):4287-96
references: 19224986
references: Science. 2009 Jul 10;325(5937):197-201
references: 19465683
references: Lancet. 2005 Oct 1;366(9492):1175-81
references: 16198766
references: Vet Rec. 2003 Jul 5;153(1):9-13
references: 12877210
references: Lancet Infect Dis. 2012 Jan;12(1):36-44
references: 22032844
references: Vaccine. 2003 Mar 28;21(13-14):1375-81
references: 12615433
references: Intervirology. 2004;47(2):72-7
references: 15192270
references: Ann Intern Med. 2012 Apr 3;156(7):512-24
references: 22371849
references: PLoS One. 2012;7(1):e31006
references: 22292088
references: Arch Virol. 2008;153(11):2085-92
references: 18985274
references: Emerg Infect Dis. 2010 Jun;16(6):1029-30
references: 20507767
references: Emerg Infect Dis. 2009 Nov;15(11):1847-9
references: 19891882
references: Influenza Other Respir Viruses. 2009 Sep;3(5):233-40
references: 21462400
references: Zoonoses Public Health. 2009 Aug;56(6-7):310-25
references: 19497089
references: Antivir Ther. 2010;15(8):1151-9
references: 21149922
references: PLoS One. 2010 Feb 05;5(2):e9068
references: 20140096
references: J Gen Virol. 2008 Jan;89(Pt 1):271-276
references: 18089751
references: J Gen Virol. 2009 Apr;90(Pt 4):900-908
references: 19223487
references: Influenza Other Respir Viruses. 2009 Nov;3(6):297-314
references: 19903212